To Immunize Patients With Extensive Stage SCLC Combined With Chemo With or Without All Trans Retinoic Acid
NCT00617409
Completed
The purpose of this research study is to test a tumor (cancer) vaccine given along with chemotherapy to determine if this vaccine will increase the chances of the tumor shrinking and/or the amount of time that people who have this disease will live.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2019
Locations: H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
Conditions: Small Cell Lung Cancer
Register for Updates
Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer
NCT00005028
Completed
Phase II trial to study the effectiveness of combining paclitaxel and bryostatin 1 in treating patients who have metastatic prostate cancer that has not responded to hormone therapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/31/2019
Locations: Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland +3 locations
Conditions: Prostate Cancer
Register for Updates
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003397
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell tran... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/31/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Lymphoma
Register for Updates
A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.
NCT02021500
Completed
A study to collect survival data on patients previously enrolled in Abraxane pancreatic cancer study CA046.
Gender:
ALL
Ages:
All
Trial Updated:
10/30/2019
Locations: TGen Clinical Research Services, Scottsdale, Arizona +38 locations
Conditions: Pancreatic Cancer
Register for Updates
Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia
NCT02267707
Terminated
The purpose of this study is to determine the safety and pharmacokinetic profile of nab®-paclitaxel (ABI-007) plus gemcitabine in subjects with advanced pancreatic cancer who have cholestatic hyperbilirubinemia secondary to bile duct obstruction.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/30/2019
Locations: Mayo Clinic Arizona, Scottsdale, Arizona +5 locations
Conditions: Pancreatic Neoplasms, Cholestasis
Register for Updates
Study of 5-fluorouracil (5-FU), Nab®1-paclitaxel, Bevacizumab, Leucovorin, and Oxaliplatin in Patients With Metastatic Pancreatic Cancer
NCT02620800
Completed
The purpose of this study is to learn about the safety and potential benefit of metronomic 5-fluorouracil in combination with nab®1-paclitaxel, bevacizumab, leucovorin, and oxaliplatin in treating patients with metastatic pancreatic adenocarcinoma.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
10/21/2019
Locations: Northwestern University, Chicago, Illinois +6 locations
Conditions: Metastatic Pancreas Adenocarcinoma
Register for Updates
Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02944396
Completed
This study seeks to establish the recommended Phase 2 dose (RPTD) of veliparib in combination with nivolumab and platinum doublet chemotherapy (carboplatin/paclitaxel or carboplatin/pemetrexed) (Phase 1 portion) and to assess whether the addition of nivolumab to veliparib in combination with platinum doublet chemotherapy results will improve progression free survival (PFS) compared to veliparib with platinum doublet chemotherapy alone in participants with metastatic or advanced Non-small Cell Lu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/21/2019
Locations: University of Alabama at Birmingham - Main /ID# 155135, Birmingham, Alabama +5 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer
NCT00540514
Completed
The purpose of this study is to compare disease response of Albumin-bound paclitaxel (ABI-007) plus Carboplatin versus Taxol and Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2019
Locations: Clearview Cancer Institute Oncology Specialties, P.C., Huntsville, Alabama +36 locations
Conditions: Non-Small Cell Lung Carcinoma
Register for Updates
ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma
NCT00407407
Terminated
The primary purpose of this study is to determine the maximum tolerated dose and dose-limiting toxicities (DLTs) of weekly and every 3-weeks ABI-007 in combination with carboplatin (area under the curve \[AUC\]=6) in patients with ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/16/2019
Locations: University of Texas, MD Anderson Cancer Center, Houston, Texas
Conditions: Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
Register for Updates
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
NCT00864253
Completed
The main purpose of this research study is to compare the safety, tolerability, and anti tumor activity of an investigational drug, ABI-007 versus Dacarbazine in patients with metastatic melanoma who have not previously received chemotherapy. ABI-007 is a new preparation of the active drug paclitaxel. It contains the same medication as the prescription chemotherapy drug Abraxane®. Abraxane® is approved by the FDA for the treatment of metastatic breast cancer after failure of combination chemothe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/16/2019
Locations: University of Alabama at Birmingham, Birmingham, Alabama +111 locations
Conditions: Malignant Melanoma
Register for Updates
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00003402
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus combination chemotherapy in treating patients who have low-grade non-Hodgkin's lymphoma or chronic lymphocytic leukemia.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
10/15/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Leukemia, Lymphoma
Register for Updates
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT00003413
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients with stage III or stage IV ovarian epithelial cancer.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
10/15/2019
Locations: Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland
Conditions: Ovarian Cancer
Register for Updates